Mendelian Randomization Combined with Experimental Validation Identifies Prognostic Genes LMNB1 and PLXNB2 in the Immune Response in Multiple Myeloma
Reduced PLXNB2 expression may drive LMNB1 upregulation, suppress immune cell responses, and promote MM progression. These genes represent promising biomarkers and therapeutic targets for improving MM treatment strategies.
Authors
- Haipeng Jia
- Ruifang Qiao
- Qiuhong Kong
- Jianhao Zhao (ORCID: https://orcid.org/0000-0002-2081-7240)
- Yanchao Duan
- Fei Niu (ORCID: https://orcid.org/0000-0002-2395-7062)
- Xiaofen Zhang (ORCID: https://orcid.org/0000-0001-9957-1775)
Institutions
- Jinan Central Hospital (CN)
- Affiliated Hospital of Taishan Medical University (CN)
- Taian City Central Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Recent Patents on Anti-Cancer Drug Discovery
- Published
- 2025-10-08
- DOI
- https://doi.org/10.2174/0115748928367765250925145654
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00